Abpro Holdings, Inc. (ABP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Abpro Holdings, Inc. (ABP) has a cash flow conversion efficiency ratio of 0.146x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.28 Million) by net assets ($-15.60 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Abpro Holdings, Inc. net asset quality index to measure how much of total assets are equity-financed.
Abpro Holdings, Inc. - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Abpro Holdings, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of Abpro Holdings, Inc. to evaluate the quality of earnings relative to operating cash generation.
Abpro Holdings, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Abpro Holdings, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Renold
LSE:RNO
|
0.166x |
|
Planet Properindo Jaya Pt
JK:PLAN
|
-0.004x |
|
KWG Group Holdings Limited
F:KOU
|
0.049x |
|
East Coast Furnitech Public Company Limited
BK:ECF
|
-0.159x |
|
Crest Nicholson Holdings plc
LSE:CRST
|
0.080x |
|
Playgon Games Inc
V:DEAL
|
0.038x |
|
UTime Limited
NASDAQ:WTO
|
0.019x |
|
Rakovina Therapeutics Inc
V:RKV
|
-0.548x |
Annual Cash Flow Conversion Efficiency for Abpro Holdings, Inc. (2016–2024)
The table below shows the annual cash flow conversion efficiency of Abpro Holdings, Inc. from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see Abpro Holdings, Inc. (ABP) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-14.95 Million | $-9.03 Million | 0.604x | +594.90% |
| 2023-12-31 | $-85.14 Million | $-7.40 Million | 0.087x | -26.45% |
| 2022-12-31 | $-75.73 Million | $-8.95 Million | 0.118x | +103.31% |
| 2021-12-31 | $3.07 Million | $-10.95 Million | -3.566x | -945.73% |
| 2017-12-31 | $-22.46 Million | $-9.47 Million | 0.422x | +6.67% |
| 2016-12-31 | $-12.35 Million | $-4.88 Million | 0.395x | -- |
About Abpro Holdings, Inc.
Abpro Holdings, Inc., a biotechnology company, focuses on novel antibody constructs for immuno-oncology and ophthalmology. Its platforms include DiversImmune, a discovery platform that generates a diverse collection of proprietary antibodies against clinically validated and novel targets; and MultiMab, an engineering platform that provides the flexibility to combine antibody building blocks in di… Read more